Universität zu Köln

Berthold, Heiner K., Rizzo, Manfredi, Spenrath, Nadine, Montalto, Giuseppe, Krone, Wilhelm and Gouni-Berthold, Ioanna (2014). Effects of Lipid-Lowering Drugs on High-Density Lipoprotein Subclasses in Healthy Men-A Randomized Trial. PLoS One, 9 (3). SAN FRANCISCO: PUBLIC LIBRARY SCIENCE. ISSN 1932-6203

Full text not available from this repository.

Abstract

Context and Objective: Investigating the effects of lipid-lowering drugs on HDL subclasses has shown ambiguous results. This study assessed the effects of ezetimibe, simvastatin, and their combination on HDL subclass distribution. Design and Participants: A single-center randomized parallel 3-group open-label study was performed in 72 healthy men free of cardiovascular disease with a baseline LDL-cholesterol of 111 +/- 30 mg/dl (2.9 +/- 0.8 mmol/l) and a baseline HDL-cholesterol of 64 +/- 15 mg/dl (1.7 +/- 0.4 mmol/l). They were treated with ezetimibe (10 mg/day, n = 24), simvastatin (40 mg/day, n = 24) or their combination (n = 24) for 14 days. Blood was drawn before and after the treatment period. HDL subclasses were determined using polyacrylamide gel-tube electrophoresis. Multivariate regression models were used to determine the influence of treatment and covariates on changes in HDL subclass composition. Results: Baseline HDL subclasses consisted of 33 +/- 10% large, 48 +/- 6% intermediate and 19 +/- 8% small HDL. After adjusting for baseline HDL subclass distribution, body mass index, LDL-C and the ratio triglycerides/HDL-C, there was a significant increase in large HDL by about 3.9 percentage points (P < 0.05) and a decrease in intermediate HDL by about 3.5 percentage points (P < 0.01) in both simvastatin-containing treatment arms in comparison to ezetimibe. The parameters obtained after additional adjustment for the decrease in LDL-C indicated that about one third to one half of these effects could be explained by the extent of LDL-C-lowering. Conclusions: In healthy men, treatment with simvastatin leads to favorable effects on HDL subclass composition, which was not be observed with ezetimibe. Part of these differential effects may be due to the stronger LDL-C-lowering effects of simvastatin.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Berthold, Heiner K. UNSPECIFIED UNSPECIFIED UNSPECIFIED Rizzo, Manfredi UNSPECIFIED UNSPECIFIED UNSPECIFIED Spenrath, Nadine UNSPECIFIED UNSPECIFIED UNSPECIFIED Montalto, Giuseppe UNSPECIFIED UNSPECIFIED UNSPECIFIED Krone, Wilhelm UNSPECIFIED UNSPECIFIED UNSPECIFIED Gouni-Berthold, Ioanna UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-443181
DOI:	10.1371/journal.pone.0091565
Journal or Publication Title:	PLoS One
Volume:	9
Number:	3
Date:	2014
Publisher:	PUBLIC LIBRARY SCIENCE
Place of Publication:	SAN FRANCISCO
ISSN:	1932-6203
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language EZETIMIBE AND/OR SIMVASTATIN; CORONARY-ARTERY-DISEASE; HDL PARTICLE-SIZE; PRIMARY HYPERCHOLESTEROLEMIA; CARDIOVASCULAR EVENTS; CHOLESTEROL LEVELS; HEART-DISEASE; COMBINATION; RISK; LDL Multiple languages Multidisciplinary Sciences Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/44318